As more innovators join the digital therapeutics (DTx) landscape, understanding the intricacies of running clinical trials in Europe becomes increasingly essential. Navigating the regulatory framework for digital therapeutics in the EU market can be an arduous journey. However, with an understanding of the country-specific regulatory guidelines, rigorous trial design, the journey to commercialization, and lessons from those already in the field, success is achievable. Providers and innovators ready to explore this growing space must be willing to learn and adapt quickly to actualize their market potential.
In this webinar led by the Digital Therapeutics Alliance, we sit down with Perfood and Poppins leadership to talk about the considerations for conducting impactful DTx trials in the European Union (EU) market, specifically focusing on the German DiGA and the French PECAN regulatory bodies.
Tune in to discover how CROs in the DTx space help sponsors navigate these hurdles to successfully conduct clinical trials, delivering essential digital health interventions to patients faster.
Lindus Health and Quotient Sciences Partner to Accelerate Drug Development from First-in-Human to Pivotal Trials
This collaboration is essential to eliminating traditional barriers in patient recruitment and reducing friction when transitioning between development stages and CRO partners, ultimately accelerating the delivery of breakthrough treatments to patients.
